Further to the announcement made by PureTech Health plc (“PureTech”) on 7 October 2022, Nektar announces that it has mutually agreed with PureTech to terminate discussions regarding a potential business combination.
Â
Morgan Stanley Maintains Equal-Weight on Ventas, Raises Price Target to $54
Morgan Stanley analyst Richard Hill maintains Ventas (NYSE:VTR) with a Equal-Weight and raises the price target from $52 to $54.